Open Forum Infect Dis. 2017 May 5;4(2):ofx040.
Isavuconazole is a new triazole that is approved for primary therapy of invasive aspergillosis. We provide the first report of a patient with allergic bronchopulmonary aspergillosis (ABPA) who was successfully treated with isavuconazole with marked improvement and minimal adverse effects. We further review the literature on antifungal management of ABPA. KEYWORDS: allergic bronchopulmonary aspergillosis; antifungal therapy; isavuconazole.